PAREXEL International Corporation a today announced that its technology subsidiary Perceptive Informatics, Inc. has been selected by Astellas Pharma Europe Limited
BOSTON, May 22 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) today announced that its technology subsidiary Perceptive Informatics, Inc. has been selected by Astellas Pharma Europe Limited (http://www.astellas.com/eu) to supply its clinical trial management system (CTMS).
In a review of 10 vendors, Astellas Pharma Europe Limited selected Perceptive's IMPACT(TM) software to replace all of its existing CTMS systems, integrate with the company's other system applications, and to enable Astellas Pharma Europe Limited more efficient management of its clinical development programs.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.